HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc... ( COLORADO SPRINGS Colo. and REYKJAVIK ...)

HOME >> BIOLOGY >> TECHNOLOGY

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services

Date:12/3/2008

COLORADO SPRINGS, Colo. and REYKJAVIK, Iceland, Dec. 3 /PRNewswire/ -- HemoGenix(R) and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO(R) Assay Kits and HALO(R) Contract Research Services where the response of human blood-forming cells is detected.

ORF Genetics produces a large number of growth factors and cytokines using barley seed as the production host. Their Orfeus(TM) Expression System, comprised of a barley endosperm expression background, gf22 expression cassette, HEKLAgro(TM) cultivation technology, and the production of isogenic lines for seed banking, makes this the most efficient and "green" production of human growth factors and cytokines for R&D medical research, cellular therapy, regenerative medicine, cosmetics and biopharma. ORF Genetics products are free of contaminants for bacterial, viral and prion components; non- pyrogenic; endotoxin-free; and perfectly safe according to FDA guidelines.

Through close collaboration, HemoGenix(R) has tested the growth factors and cytokines produced by ORF Genetics and found them to produce similar, if not superior, potency for growth of human bone marrow, cord blood and peripheral blood cells using its HALO(R) ATP-based, bioluminescence proliferation/cytotoxicity assay platform. The growth factors and cytokines needed to stimulate and detect various blood-forming stem and progenitor cell populations will now be incorporated into the complete line of HALO(R) Assay Kits produced by HemoGenix(R). This is particularly important for the family of HALO(R) quality control and potency assays used to ensure "stem cell quality" and "stem cell potency" for release of stem cell products, particularly umbilical cord blood, prior to transplantation into patients.

HemoGenix(R) will also incorporate ORF Genetics growth factors and cytokines into its HALO(R) Hemotoxici
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease

Post Your Comments:

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc...( COLORADO SPRINGS Colo. and REYKJAVIK ...)